0
Delivery Systems for the BMPs   |    
TGF-β1 Release from Biodegradable Polymer Microparticles: Its Effects on Marrow Stromal Osteoblast Function
Lichun Lu, PhD; Michael J. Yaszemski, MD, PhD; Antonios G. Mikos, PhD
View Disclosures and Other Information
Investigation performed at the Departments of Bioengineering and Chemical Engineering, Rice University, Houston, Texas
Lichun Lu, PhD
Michael J. Yaszemski, MD, PhD
Departments of Orthopedic Surgery and Bioengineering, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, U.S.A.

Antonios G. Mikos, PhD
Department of Bioengineering, Rice University, 6100 Main Street, MS-142, Houston, TX 77005-1892, U.S.A. E-mail address: mikos@rice.edu

In support of their research or preparation of this manuscript, one or more of the authors received grants or outside funding from NIH (R01-AR44381). None of the authors received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, educational institution, or other charitable or nonprofit organization with which the authors are affiliated or associated.

J Bone Joint Surg Am, 2001 Apr 01;83(1 suppl 2):S82-S92
5 Recommendations (Recommend) | 3 Comments | Saved by 3 Users Save Case

Abstract

Background: Controlled release of transforming growth factor-&betabeta;1 (TGF-&betabeta;1) to a bone defect may be beneficial for the induction of a bone regeneration cascade. The objectives of this work were to assess the feasibility of using biodegradable polymer microparticles as carriers for controlled TGF-&betabeta;1 delivery and the effects of released TGF-&betabeta;1 on the proliferation and differentiation of marrow stromal cells in vitro.

Methods: Recombinant human TGF-&betabeta;1 was incorporated into microparticles of blends of poly(DL-lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG). Fluorescein isothiocynate-labeled bovine serum albumin (FITC-BSA) was co-encapsulated as a porogen. The effects of PEG content (0, 1, or 5% by weight [wt%]) and buffer pH (3, 5, or 7.4) on the protein release kinetics and the degradation of PLGA were determined in vitro for as long as 28 days. Rat marrow stromal cells were seeded on a biodegradable poly(propylene fumarate) (PPF) substrate. The dose response and biological activity of released TGF-&betabeta;1 was determined after 3 days in culture. The effects of TGF-&betabeta;1 released from PLGA/PEG microparticles on marrow stromal cell proliferation and osteoblastic differentiation were assessed during a 21-day period.

Results: TGF-&betabeta;1 was encapsulated along with FITC-BSA into PLGA/PEG blend microparticles and released in a multiphasic fashion including an initial burst for as long as 28 days in vitro. Increasing the initial PEG content resulted in a decreased cumulative mass of released proteins. Aggregation of FITC-BSA occurred at lower buffer pH, which led to decreased release rates of both proteins. The degradation of PLGA was increased at higher PEG content and significantly accelerated at acidic pH conditions. Rat marrow stromal cells cultured on PPF substrates showed a dose response to TGF-&betabeta;1 released from the microparticles similar to that of added TGF-&betabeta;1, indicating that the activity of TGF-&betabeta;1 was retained during microparticle fabrication and after growth factor release. At an optimal TGF-&betabeta;1 dosage of 1.0 ng/ml after 3 days, the released TGF-&betabeta;1 enhanced the proliferation and osteoblastic differentiation of marrow stromal cells over 21 days of culture, with increased total cell number, alkaline phosphatase activity, and osteocalcin production.

Conclusions: PLGA/PEG blend microparticles can serve as delivery vehicles for controlled release of TGF-&betabeta;1, and the released growth factor enhances marrow stromal cell proliferation and osteoblastic differentiation in vitro.

Clinical Relevance: Controlled release of TGF-&betabeta;1 from PLGA/PEG microparticles is representative of emerging tissue engineering technologies that may modulate cellular responses to encourage bone regeneration at a skeletal defect site.

Figures in this Article
    Sign In to Your Personal ProfileSign In To Access Full Content
    Not a Subscriber?
    Get online access for 30 days for $35
    New to JBJS?
    Sign up for a full subscription to both the print and online editions
    Register for a FREE limited account to get full access to all CME activities, to comment on public articles, or to sign up for alerts.
    Register for a FREE limited account to get full access to all CME activities
    Have a subscription to the print edition?
    Current subscribers to The Journal of Bone & Joint Surgery in either the print or quarterly DVD formats receive free online access to JBJS.org.
    Forgot your password?
    Enter your username and email address. We'll send you a reminder to the email address on record.

     
    Forgot your username or need assistance? Please contact customer service at subs@jbjs.org. If your access is provided
    by your institution, please contact you librarian or administrator for username and password information. Institutional
    administrators, to reset your institution's master username or password, please contact subs@jbjs.org

    References

    Accreditation Statement
    These activities have been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Academy of Orthopaedic Surgeons and The Journal of Bone and Joint Surgery, Inc. The American Academy of Orthopaedic Surgeons is accredited by the ACCME to provide continuing medical education for physicians.
    CME Activities Associated with This Article
    Submit a Comment
    Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
    Comments are moderated and will appear on the site at the discretion of JBJS editorial staff.

    * = Required Field
    (if multiple authors, separate names by comma)
    Example: John Doe





    Related Content
    The Journal of Bone & Joint Surgery
    JBJS Case Connector
    Topic Collections
    Related Audio and Videos
    Clinical Trials
    Readers of This Also Read...
    JBJS Jobs
    04/16/2014
    OH - OhioHealth Research and Innovation Institute (OHRI)
    10/12/2011
    NY - Modern Chiropractic Care, P.C.